secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pediatrix Medical Group, Inc. (MD)
CIK:        0000893949
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001193125-25-006190
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025
-----------------------------------------------------------------------------

- Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.
- Employment agreement: $1M base salary, $2M one-time cash retention award, annual bonus target 150% of salary.
- Equity transformation award: 640,000 performance share units with stock price hurdles of 125%, 150%, and 175%.
- Annual equity grants of at least $5.5M; severance for cause-less termination: 2x base+bonus, 3x under change in control.
- Dr. Swift's departure is termination without cause; he will receive severance benefits under prior employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/0001193125-25-006190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/893949/000119312525006190/d855972d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-006190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer